Sharon Rosenzweig-Lipson
Works at
Lead investigator
Sources: openalex.org
Grants and prizes
Alzheimer's Drug Discovery Foundation
Drug Discovery, In Vivo Characterization of a GABA-A alpha-5 Positive Allosteric Modulator, ADDF-21150875, 2019–2021, 9 Sept 2019
Alzheimer's Drug Discovery Foundation
Clinical, Accelerating Manufacture of Clinical Supplies for Initiation of Patient Enrollment in the HOPE4MCI Phase 3 Trial (AgeneBio, AGB101), ADDF-3704, 2017–2018, 9 Nov 2017
Alzheimer's Drug Discovery Foundation
Drug Discovery, GABA-A alpha-5 Positive Allosteric Modulators for the treatment of aMCI due to AD., ADDF-3649, 2017–2018, 1 May 2017
Sources: openalex.org